Holen Sie sich die Stockscreener-App
30.15
1.12%
-0.34
Handel nachbörslich:
30.15
Schlusskurs vom Vortag:
$30.49
Offen:
$30.51
24-Stunden-Volumen:
412.55K
Relative Volume:
0.43
Marktkapitalisierung:
$1.75B
Einnahmen:
$868.45M
Nettoeinkommen (Verlust:
$158.69M
KGV:
11.13
EPS:
2.7087
Netto-Cashflow:
$328.64M
1W Leistung:
+0.20%
1M Leistung:
-5.69%
6M Leistung:
-12.12%
1J Leistung:
-11.66%
1-Tages-Spanne:
$29.96
$30.81
1-Wochen-Bereich:
$29.67
$31.54
52-Wochen-Spanne:
$25.52
$40.87
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Firmenname
Harmony Biosciences Holdings Inc
Sektor
Branche
Telefon
(484) 539-9800
Adresse
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
30.15 | 1.77B | 868.45M | 158.69M | 328.64M | 2.7087 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-23 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2026-02-23 | Herabstufung | Truist | Buy → Hold |
| 2026-02-11 | Fortgesetzt | UBS | Neutral |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-10 | Eingeleitet | UBS | Buy |
| 2024-06-21 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Herabstufung | Goldman | Neutral → Sell |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-14 | Hochstufung | Janney | Neutral → Buy |
| 2022-10-14 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-04 | Eingeleitet | Raymond James | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-03-29 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-14 | Eingeleitet | Goldman | Neutral |
| 2020-09-14 | Eingeleitet | Jefferies | Buy |
| 2020-09-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
Trading the Move, Not the Narrative: (HRMY) Edition - Stock Traders Daily
HRMY SEC FilingsHarmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright reiterates Harmony Biosciences stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Harmony Revenue Rises as WAKIX Franchise Expands - MyChesCo
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities - Quantisnow
A beaten-down biotech just lost a meaningful backer — should you care? - sharewise.com
A beaten-down biotech just lost a meaningful backer — should you care? - The Motley Fool
Harmony Biosciences Holdings, Inc.Common Stock (NQ: HRMY - FinancialContent
Harmony Biosciences (HRMY) director Germano Geno J files initial insider Form 3 - Stock Titan
Harmony Biosciences (HRMY) director receives 21,872-share stock option grant - Stock Titan
Harmony Biosciences director granted 21,872 options | HRMY Insider Trading - Stock Titan
Director Graf R. Mark receives 21,872 HRMY stock options in new equity grant - Stock Titan
Harmony Biosciences (HRMY) director awarded 21,872 stock options at $30.76 strike price - Stock Titan
Director Gary Sender receives 21,872 stock options at Harmony Biosciences (HRMY) - Stock Titan
Harmony Biosciences (HRMY) CMO exercises RSUs and covers tax withholding - Stock Titan
Harmony Biosciences (HRMY) CFO granted 164,309 stock options at $29.29 strike - Stock Titan
Harmony Biosciences (HRMY) CFO files initial Form 3 insider report - Stock Titan
Earnings Dip, Revenue Growth and Patent Moves Might Change The Case For Investing In Harmony Biosciences (HRMY) - simplywall.st
Number of shareholders of Harmony Biosciences Holdings, Inc. – NASDAQ:HRMY - TradingView
Harmony Biosciences Shareholders Approve Governance Measures at Meeting - TipRanks
Harmony Biosciences (HRMY) shareholders elect directors, ratify auditor and back pay - Stock Titan
Harmony Biosciences Holdings Inc Annual Shareholders Meeting Transcript - GuruFocus
Harmony Biosciences’ Four Key Pillars to Drive Value Creation - Sleep Review
Investors Can Find Comfort In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Quality - simplywall.st
Harmony Biosciences Holdings, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HRMY) 2026-05-13 - Seeking Alpha
(HRMY) Volatility Zones as Tactical Triggers - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Liquidia Technologies (LQDA) - The Globe and Mail
Harmony Biosciences Holdings (HRMY) Announces Financial Results for Q1 2026 - Insider Monkey
H.C. Wainwright Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Harmony Biosciences Holdings, Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next - simplywall.st
Earnings Miss: Harmony Biosciences Holdings, Inc. Missed EPS By 21% And Analysts Are Revising Their Forecasts - Yahoo Finance
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised - TradingView
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by Vanguard Group Inc. - MarketBeat
10 Best Healthcare Stocks to Buy for the Long Term - Insider Monkey
Harmony Biosciences Holdings, Inc. (HRMY) Q1 earnings and revenues miss estimates - MSN
Harmony Biosciences Holdings HRMY Margin Compression Challenges Bullish Valuation Narratives - Sahm
Harmony Biosciences Holdings (HRMY) Valuation After Q1 2026 Earnings Miss And Profitability Concerns - Yahoo Finance
Harmony outlines $1B-$1.04B 2026 net revenue plan while targeting pitolisant GR PDUFA in Q1 2027 - MSN
Wall Street analysts think Harmony Biosciences (HRMY) could surge 34.81%: Read this before placing a bet - MSN
Is Harmony Biosciences Holdings, Inc. (HRMY) One of The Best Small Cap Value Stocks to Buy? - Insider Monkey
[144] Harmony Biosciences Holdings, Inc. SEC Filing - Stock Titan
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $45 - Moomoo
Should Harmony Biosciences’ Softer Q1 2026 Earnings and Upbeat Forecasts Require Action From HRMY Investors? - Yahoo Finance
Harmony Biosciences Q1 Earnings Call Highlights - Yahoo Finance
Harmony Biosciences Q1 2026 Earnings Call Transcript - MarketBeat
5 Best Small-Cap Value Stocks to Buy - Insider Monkey
HRMY: Q1 revenue up 17% to $215.4M; strong WAKIX growth and pipeline advance support $1B+ guidance - TradingView
Why Is Harmony Biosciences Holdings (HRMY) Dropping 8.4%? - AlphaStreet
HRMY: Q1 revenue rose 17% to $215.4M, with strong WAKIX growth and guidance reaffirmed - TradingView
Finanzdaten der Harmony Biosciences Holdings Inc-Aktie (HRMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):